Finally, we examined DDR1 invasive activity and its inhibition by nilotinib in patient‐derived CRC cell lines we recently generated from metastatic tumours and circulating CRC cells in blood samples (Grillet et al, 2017). The gene discussed is DDR1; the disease is colorectal carcinoma.